High incidence of arterial thrombosis in young patients treated for multiple myeloma: Results of a prospective cohort study

Blood

Volumn 116, Issue 1, 2010, Pages 22-26

  Libourel, Eduard J ^a   Sonneveld, Pieter ^a   Van Holt, Bronno Der ^a   De Maat, Moniek P M ^a   Leebeek, Frank W G ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 8; BORTEZOMIB; CLOPIDOGREL; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; NADROPARIN; THALIDOMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; COHORT ANALYSIS; DISEASE ASSOCIATION; DRUG MEGADOSE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SMOKING; THROMBOSIS; INCIDENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; STATISTICS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CLINICAL TRIALS, PHASE III AS TOPIC; DEXAMETHASONE; DOXORUBICIN; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT (HEALTH CARE); PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PYRAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; THALIDOMIDE; THROMBOSIS; VINCRISTINE;

EID: 77955913504     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-12-257519     Document Type: Article

References (25)

1. Kristinsson SY, Fears TR, Gridley G, et al. Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood. 2008;112(9):3582-3586.
2. Auwerda JJ, Sonneveld P, de Maat MP, Leebeek FW. Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma. Haematologica. 2007;92(2):279-280. (Pubitemid 46852441)
3. van Marion AM, Auwerda JJ, Minnema MC, et al. Hypofibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis. Thromb Haemost. 2005;94(6):1341-1343.
4. Elice F, Fink L, Tricot G, Barlogie B, Zangari M. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol. 2006;134(4):399-405. (Pubitemid 44079553)
5. Goz M, Eren MN, Cakir O. Arterial thrombosis and thalidomide. J Thromb Thrombolysis. 2008;25(2):224-226.
6. Altintas A, Ayyildiz O, Atay AE, Cil T, Isikdogan A, Muftuoglu E. Thalidomide-associated arterial thrombosis: two case reports. Ann Acad Med Singapore. 2007;36(4):304-306. (Pubitemid 47309195)
7. Alkindi S, Dennison D, Pathare A. Arterial and venous thrombotic complications with thalidomide in multiple myeloma. Arch Med Res. 2008;39(2):257-258. (Pubitemid 350302079)
8. Scarpace SL, Hahn T, Roy H, et al. Arterial thrombosis in four patients treated with thalidomide. Leuk Lymphoma. 2005;46(2):239-242. (Pubitemid 40185954)
9. Raven W, Berghout A, van Houten A, Leebeek FW. Treatment of multiple myeloma and arterial thrombosis. Ann Hematol. 2010;89(4):419-420.
10. Lokhorst HM, Schmidt-Wolf I, Sonneveld P, et al. Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica. 2008;93(1):124-127. (Pubitemid 351156161)
11. Sonneveld P, van der Holt B, Schmidt-Wolf IG, et al. First analysis of HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, adriamycine, dexamethasone (PAD) vs VAD as induction treatment prior to high dose melphalan (HDM) in patients with newly diagnosed multiple myeloma (MM). Blood (ASH Annual Meeting Abstracts). 2008;112:Abstract 653.
12. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412-3420.
13. Clauss A. Rapid physiological coagulation method in determination of fibrinogen. Acta Haematol. 1957;17(4):237-246.
14. Wolf M, Boyer-Neumann C, Leroy-Matheron C, et al. Functional assay of protein S in 70 patients with congenital and acquired disorders. Blood Coagul Fibrinolysis. 1991;2(6):705-712.
15. Volksgezondheid Toekomst Verkenning, Nationaal Kompas Volksgezondheid. Bilthoven: RIVM, Nationaal Kompas Volksgezondheid, versie 3.19; September 24, 2009. http://www.nationaalkompas.nl. Accessed November 5, 2009.
16. Kristinsson SY, Pfeiffer R, Bjorkholm M, et al. Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood (ASH Annual Meeting Abstracts). 2009;Abstract 1872.
17. van Marion AM, Auwerda JJ, Lisman T, et al. Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens. Leuk Res. 2008;32(7):1078-1084.
18. Minnema MC, Fijnheer R, De Groot PG, Lokhorst HM. Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J Thromb Haemost. 2003;1(3):445-449.
19. Petri M, Lakatta C, Magder L, Goldman D. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med. 1994;96(3):254-259. (Pubitemid 24099225)
20. Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007;109(5):1878- 1886. (Pubitemid 46348183)
21. Swerdlow AJ, Higgins CD, Smith P, et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst. 2007;99(3):206-214.
22. Rietbrock S, Heeley E, Plumb J, van Staa T. Chronic atrial fibrillation: incidence, prevalence, and prediction of stroke using the congestive heart failure, hypertension, age >75, diabetes mellitus, and prior stroke or transient ischemic attack (CHADS2) risk stratification scheme. Am Heart J. 2008;156(1):57-64. (Pubitemid 351877101)
23. Bank I, van de Poel MH, Coppens M, et al. Absolute annual incidences of first events of venous thromboembolism and arterial vascular events in individuals with elevated FVIII:c: a prospective family cohort study. Thromb Haemost. 2007;98(5):1040-1044. (Pubitemid 350091133)
24. Gomperts ED, Shulman G, Lynch SR. Factor VIII and factor-VIII-related antigen in multiple myelomatosis and related conditions. Br J Haematol. 1976;32(2):249-255.
25. Palumbo A, Rajkumar SV, Dimopoulos MA, et al. International Myeloma Working Group: prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22(2):414-423.